Milk thistle for chemotherapy-associated liver injury

Evidence label: Insufficient / no demonstrated clinical benefit · Clinical goal: prevent or improve chemotherapy-associated liver-test abnormalities

Evidence at a glance

Population: children with acute lymphoblastic leukemia and adults receiving breast-cancer chemotherapy.
Intervention: milk-thistle or silymarin preparations; doses and formulations varied.
Result: small randomized studies show laboratory trends, but primary liver-test outcomes were often not significantly different.

What was studied

A double-blind pilot randomized 50 children with acute lymphoblastic leukemia and grade 2 or worse hepatic toxicity to a milk-thistle preparation or placebo for 28 days during maintenance therapy.

At day 28 there was no significant between-group change in mean ALT, AST or bilirubin. Some delayed or secondary laboratory signals favored milk thistle, but the pilot was not designed to establish fewer chemotherapy holds, hospitalizations or liver failures.

A 30-person triple-blind breast-cancer trial tested silymarin 140 mg three times daily during AC-T chemotherapy; an ultrasound trend favored silymarin but was not statistically significant (P=.083).

What the evidence shows

The evidence does not establish that milk thistle prevents clinically meaningful liver injury or allows safer delivery of chemotherapy. Liver-enzyme changes are surrogate outcomes and can fluctuate for many reasons.

NCCIH describes clinical evidence for chemotherapy-related liver problems as conflicting or too limited for conclusions.

Limits and uncertainty

Trials are small, formulations differ and many outcomes are laboratory measures. Pediatric leukemia and adult breast-cancer regimens cannot be pooled casually.

Some newer studies were abstract-level only; exact adherence, missing data and conflict-of-interest details were not independently verified.

Safety and practical context

Milk thistle may cause gastrointestinal symptoms or allergy, especially in people sensitive to ragweed-family plants. NCCIH warns that commercial products can have inaccurate silymarin content or contamination.

Because liver injury can come from chemotherapy, infection, biliary obstruction, tumor, alcohol, other medicines or supplements, abnormal tests need clinical assessment rather than supplement substitution.

Questions for the care team

What is the likely cause and severity of the liver-test abnormality?
Could this product interact with chemotherapy or another liver-metabolized medicine?
Which clinical endpoint—fewer holds, dose reductions or symptoms—would show meaningful benefit?

Sources

Literature searched: October 15, 2026 · Record appraised: October 15, 2026

Educational evidence summary, not personal medical advice. Research regimens describe what was studied; they are not personal prescribing instructions and should not replace cancer treatment or individualized supportive care.